Canada’s Valeant Pharmaceuticals reported a better-than-expected quarterly profit and said it expected to repay more than $5 billion in debt earlier than it had targeted, sending its shares up 10 percent.
Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company’s business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.
